{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=teclistamab", "query": { "intervention": "teclistamab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 37, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=teclistamab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T03:33:49.975Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05469893", "title": "Immuno-PRISM (PRecision Intervention Smoldering Myeloma)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-risk Smoldering Multiple Myeloma", "Smoldering Multiple Myeloma", "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Irene Ghobrial, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2022-08-10", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 3, "location_summary": "Denver, Colorado • Boston, Massachusetts • Portland, Oregon", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05469893" }, { "nct_id": "NCT07581704", "title": "Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Teclistamab", "type": "BIOLOGICAL" }, { "name": "Talquetamb", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Christopher Strouse", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-06-01", "completion_date": "2029-10-01", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07581704" }, { "nct_id": "NCT04722146", "title": "A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Nirogacestat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2021-03-12", "completion_date": "2027-10-13", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 14, "location_summary": "Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04722146" }, { "nct_id": "NCT04557098", "title": "A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2020-09-17", "completion_date": "2027-05-28", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04557098" }, { "nct_id": "NCT05243797", "title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Myeloma Network B.V.", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1594, "start_date": "2022-09-08", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243797" }, { "nct_id": "NCT07728188", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2026-11-30", "completion_date": "2033-02", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 24, "location_summary": "Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07728188" }, { "nct_id": "NCT05972135", "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Oral Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-10-23", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 17, "location_summary": "Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05972135" }, { "nct_id": "NCT03145181", "title": "Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "Teclistamab (IV)", "type": "DRUG" }, { "name": "Teclistamab(SC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2017-05-16", "completion_date": "2027-08-24", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 5, "location_summary": "Duarte, California • Denver, Colorado • New York, New York + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03145181" }, { "nct_id": "NCT06352866", "title": "Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Cytokine Release Syndrome", "Refractory Multiple Myeloma", "Immune Effector Cell Associated Neurotoxicity Syndrome" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Teclistamab(FDA-approved)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jack Khouri, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-01-01", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06352866" }, { "nct_id": "NCT04108195", "title": "A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2020-02-21", "completion_date": "2027-04-07", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-05T03:33:49.975Z", "location_count": 10, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04108195" } ] }